You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

US WorldMeds acquires Orbus Therapeutics

Enhertu wins EU approval for HER2-positive early breast cancer treatment

Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers

Cumberland Pharmaceuticals to submit New Drug Application for ifetroban

Labcorp, Charles River and FDA collaborate on advancing preclinical methods for evaluating drug abuse potential

ProBio's Nanjing biologics manufacturing facility completes Chinese regulatory pre-approval inspection

Lynch Regenerative Medicine's Phase IIb clinical trial of rhPDGF-BB injection cleared by FDA

European Commission approves Novartis' Cosentyx for polymyalgia rheumatica

Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system

GSK wins US FDA approval for chronic hepatitis B treatment Hibsago

Solventum's combined use of Restrata Matrix and Solventum VAC Therapy receives FDA 510(k) clearance

Vivacta Bio and Grit Bio's in vivo CAR-T therapy GT801 receives US FDA Orphan Drug Designation for autoimmune haemolytic anaemia

Viatris' RYZUMVI receives US FDA Approval to treat presbyopia

Omeros receives negative EU opinion on narsoplimab after re-examination

Ionis' TRYNGOLZA recommended for EU approval in severe hypertriglyceridemia

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026